



Professor Eric Klein, MD of Cleveland Clinic's Lerner College of Medicine Named to Cellanyx Scientific Advisory Board; SAB Chair Grannum Sant, MD, FRCS, FACS Appointed to Board of Directors

Beverly, MA, August 2, 2017 – Cellanyx today announced that Eric Klein, MD, Andrew C. Novick Distinguished Chair of the Glickman Urological and Kidney Institute and Professor of Surgery in the Lerner College of Medicine of the Cleveland Clinic, has joined to the company's Scientific Advisory Board (SAB). Cellanyx also appointed Grannum Sant, MD, FRCS, FACS, Chairman of the SAB to the company's board of directors.

"Dr. Klein is a world leading authority on prostate cancer biology and disease management," said Dr. Sant. "He brings to Cellanyx deep expertise in clinical urologic oncology which will be critical as the company enters the next phase of development for its prostate cancer risk stratification test based on its live tumor cell, phenotypic platform."

"Dr. Sant's appointment to the Board of Directors reflects his outstanding leadership of the Scientific Advisory Board and many contributions across all of Cellanyx's activities," said Pravin Chaturvedi, PhD, chairman of the Cellanyx board of directors. "We look forward to his continued guidance in this expanded role."

Dr. Klein joined the staff of the Cleveland Clinic in 1989 and currently serves as a member of the Department of Cancer Biology of the Cleveland Clinic Lerner Research Institute, the Taussig Cancer Institute, and the Genitourinary Malignancies Program in the Case Comprehensive Cancer Center. Dr. Klein's clinical and research interests cover all stages of prostate cancer with a focus on genomics and clinical trials. Under his direction, the Prostate Cancer Research Program has been recognized as "Program of the Year" by the Cleveland Clinic. He has served as Chairman of the Localized Prostate Cancer Committee of the Southwest Oncology Group and was the National Study Coordinator for the NCI-sponsored Selenium and Vitamin E Cancer Prevention Trial (SELECT). Dr. Klein has contributed more than 400 papers to the scientific literature, authored or edited 8 books on urologic malignancies, and serves as the Editor-in-Chief of *Urology*. He has delivered more than 200 invited scientific lectures including 13 named lectureships, and has served as a Visiting Professor at more than 50 institutions around the world. Dr. Klein holds an MD degree from the University of Pittsburgh (PA).

Dr. Sant is a leading expert in urologic diseases, with 30 years of academic and biopharmaceutical industry experience. He is currently Professor (Adjunct) of Urology at Tufts University School of Medicine where he previously served as Chair of the Urology and he has held positions as VP of Medical Affairs at pharmaceutical companies Sanofi (Urology and

Oncology) and Genzyme (Rare Orphan Diseases). Dr. Sant received his medical degree from Trinity College, Dublin University and completed his urology residency at Tufts University. He has published two textbooks in urology, authored over 120 peer-reviewed publications and is on the editorial boards of a number of national and international journals.

About Cellanyx

Cellanyx is developing a first-in-class live tumor cell, phenotypic platform for precision risk stratification in cancer to help clinical treatment decision making. The company's platform directly assesses the dynamic behavior of thousands of live tumor cells and their phenotypic biomarkers and quantifies the hallmarks of cancer and cancer aggressiveness such as cell movement and protein dynamics. Big data and machine vision learning techniques are utilized to select biomarkers that predict adverse pathology at the time of surgery. The company's lead test, for prostate cancer, has demonstrated clinical proof of concept in a study of more than 300 tissue samples from radical prostatectomy patients. Learn more at www.cellanyx.com.

Contact:

Ashok Chander, CEO
ashok@cellanyx.com
978 473 7883

Robert Gottlieb, RMG Associates, LLC
Robertmg52@gmail.com
857 891 9091

###